We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
Read MoreHide Full Article
AbbVie, Inc. (ABBV - Free Report) announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis.
Please note that Skyrizi was first approved to treat moderate-to-severe plaque psoriasis in 2019. Active psoriatic arthritis is the second FDA-approved indication for the drug. The drug is approved for both these indications in Europe as well.
The FDA approval for the label expansion of Skyrizi to include active psoriatic arthritis was based on positive top-line data from two pivotal studies — KEEPsAKE-1 and KEEPsAKE-2. Data from these studies demonstrated that the proportion of patients who achieved the primary endpoint of ACR20 response or at least a 20% reduction in the number of both tender and swollen joint counts at week 24 following treatment with Skyrizi was significantly higher compared to treatment with placebo. The drug also showed significant improvements in skin clearance, physical function and minimal disease activity in the pivotal studies.
Data from these pivotal studies supported the potential of Skyrizi in improving several psoriatic arthritis symptoms, which include joint pain, enthesitis and dactylitis.
AbbVie’s stock has risen 19.4% in the past year compared with an increase of 9.7% for the industry.
Image Source: Zacks Investment Research
Sykrizi is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23, a cytokine, which is involved in inflammatory processes.
AbbVie is developing Skyrizi in collaboration with Boehringer Ingelheim, with AbbVie leading the global development and commercialization of Skyrizi. The companies are currently seeking another label expansion of Skyrizi to include patients with Crohn’s disease. Regulatory applications seeking approval for the drug as a potential treatment for Crohn’s disease are under review in the United States and Europe.
AbbVie remains focused on strengthening its focus on Skyrizi and its other inflammatory drug Rinvoq to gradually lower its dependence on Humira, the company’s blockbuster drug, sales of which are declining due to biosimilars that are eroding AbbVie’s yearly international sales. Humira biosimilars are expected to be launched in the United States in 2023.
Both Skyrizi and Rinvoq demonstrated differentiated clinical profiles compared to Humira. With many new indications coming in the next couple of years, AbbVie expects sales of these two drugs to be higher with the potential to replace Humira.
Skyrizi generated sales worth $2.04 billion in the first nine months of 2021 while Rinvoq generated sales worth $1.33 during the same period.
Roche’s earnings per share estimates for 2021 have increased from $3.04 to $3.12 in the past 30 days.
Shares of Roche have risen 7.5% in the past year.
Pfizer’s earnings estimates per share for 2022 have increased from $5.66 to $5.80 in the past 30 days. Shares of Pfizer have risen 41.6% in the past year.
Earnings of Pfizer beat estimates in three of the last four quarters and missed expectations on one occasion, the average surprise being 10.85%.
Vertex’s earnings per share estimates for 2022 have improved from $13.32 to $13.35 in the past 30 days.
Earnings of Vertex beat estimates in three of the last four quarters and missed expectations once, the earnings surprise being 8.00%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
AbbVie, Inc. (ABBV - Free Report) announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis.
Please note that Skyrizi was first approved to treat moderate-to-severe plaque psoriasis in 2019. Active psoriatic arthritis is the second FDA-approved indication for the drug. The drug is approved for both these indications in Europe as well.
The FDA approval for the label expansion of Skyrizi to include active psoriatic arthritis was based on positive top-line data from two pivotal studies — KEEPsAKE-1 and KEEPsAKE-2. Data from these studies demonstrated that the proportion of patients who achieved the primary endpoint of ACR20 response or at least a 20% reduction in the number of both tender and swollen joint counts at week 24 following treatment with Skyrizi was significantly higher compared to treatment with placebo. The drug also showed significant improvements in skin clearance, physical function and minimal disease activity in the pivotal studies.
Data from these pivotal studies supported the potential of Skyrizi in improving several psoriatic arthritis symptoms, which include joint pain, enthesitis and dactylitis.
AbbVie’s stock has risen 19.4% in the past year compared with an increase of 9.7% for the industry.
Image Source: Zacks Investment Research
Sykrizi is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23, a cytokine, which is involved in inflammatory processes.
AbbVie is developing Skyrizi in collaboration with Boehringer Ingelheim, with AbbVie leading the global development and commercialization of Skyrizi. The companies are currently seeking another label expansion of Skyrizi to include patients with Crohn’s disease. Regulatory applications seeking approval for the drug as a potential treatment for Crohn’s disease are under review in the United States and Europe.
AbbVie remains focused on strengthening its focus on Skyrizi and its other inflammatory drug Rinvoq to gradually lower its dependence on Humira, the company’s blockbuster drug, sales of which are declining due to biosimilars that are eroding AbbVie’s yearly international sales. Humira biosimilars are expected to be launched in the United States in 2023.
Both Skyrizi and Rinvoq demonstrated differentiated clinical profiles compared to Humira. With many new indications coming in the next couple of years, AbbVie expects sales of these two drugs to be higher with the potential to replace Humira.
Skyrizi generated sales worth $2.04 billion in the first nine months of 2021 while Rinvoq generated sales worth $1.33 during the same period.
AbbVie Inc. Price
AbbVie Inc. price | AbbVie Inc. Quote
Zacks Rank & Stocks to Consider
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Roche (RHHBY - Free Report) , Pfizer (PFE - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) . While Roche and Pfizer sport a Zacks Rank #1 (Strong Buy), Vertex carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Roche’s earnings per share estimates for 2021 have increased from $3.04 to $3.12 in the past 30 days.
Shares of Roche have risen 7.5% in the past year.
Pfizer’s earnings estimates per share for 2022 have increased from $5.66 to $5.80 in the past 30 days. Shares of Pfizer have risen 41.6% in the past year.
Earnings of Pfizer beat estimates in three of the last four quarters and missed expectations on one occasion, the average surprise being 10.85%.
Vertex’s earnings per share estimates for 2022 have improved from $13.32 to $13.35 in the past 30 days.
Earnings of Vertex beat estimates in three of the last four quarters and missed expectations once, the earnings surprise being 8.00%, on average.